List view / Grid view
27 February 2014 | By kdm communications
Cresset is pleased to announce the release of our latest set of Pipeline Pilot components V2.0.0, including new tools for 3D visualization of field patterns, SAR data analysis and 3D-QSAR modeling...
27 February 2014 | By Novo Nordisk
The employees of Novo Nordisk A/S have conducted the election of employee representatives to the Board of Directors of Novo Nordisk A/S...
26 February 2014 | By Novartis
Novartis announced additional steps to extend its leadership in clinical trial data transparency...
26 February 2014 | By AstraZeneca
AstraZeneca announced the FDA approved orphan drug MYALEPT™ , which is indicated as an adjunct to diet as replacement therapy for the treatment of complications of leptin deficiency in patients with congenital or acquired generalised lipodystrophy...
26 February 2014 | By kdm communications
Tecan has launched the TouchTools™ PCR Wizard, an easy-to-use Freedom EVOware® add-on offering straightforward automation of PCR reaction set¬¬up on Freedom EVO® platforms...
25 February 2014 | By The European Medicines Agency
Over the past twelve months, a total of 12 medicines for the treatment of rare diseases were recommended for marketing authorisation by the European Medicines Agency’s Committee for Medicinal Products for Human Use...
25 February 2014 | By Novartis
A strong majority of Novartis shareholders today followed the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting...
25 February 2014 | By Daiichi Sankyo Company
Daiichi Sankyo has announced that its consolidated subsidiary, Ranbaxy Laboratories, will temporarily suspended shipments of active pharmaceutical ingredients (APIs) produced at its Toansa and Dewas plants in India.
24 February 2014 | By Pfizer
Pfizer Inc. announced that the Community-Acquired Pneumonia Immunization Trial in Adults achieved its primary clinical objective and both secondary clinical objectives...
24 February 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has granted its investigational DCV Dual Regimen Breakthrough Therapy Designation for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection...
24 February 2014 | By Novartis
Novartis announced that its meningococcal serogroup B vaccine, Bexsero®, will be used as part of a vaccination program at the University of California Santa Barbara and will end on March 7...
21 February 2014 | By The European Medicines Agency
The European Medicines Agency has concluded its review of Protelos/Osseor and has recommended further restricting the use of the medicine to patients who cannot be treated with other medicines approved for osteoporosis...
21 February 2014 | By Roche
New automated CINtec PLUS test improves the detection of cervical pre-cancer...
21 February 2014 | By Teva Pharmaceutical Industries Ltd
Innovative new inhaler for asthma and COPD patients
21 February 2014 | By Novartis
Lucentis® (ranibizumab) has been approved by Japanese regulatory bodies for a fourth indication: the treatment of patients with diabetic macular edema, a leading cause of vision loss among patients with diabetes...
